RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs
09 nov. 2023 12h58 HE
|
RetinalGeniX Technologies, Inc.
RetinalGeniX Announces Therapeutic Solutions Being Developed for Dry Age-Related Macular Degeneration
and Alzheimer’s Syndrome.
Athira Pharma to Participate in Jefferies London Healthcare Conference
08 nov. 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam™ Image Visualization Device
08 nov. 2023 05h45 HE
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC and AVANIA CRO CONTRACT to GUIDE the DEVELOPMENT of TWO DRUG THERAPIES and the RETINALCAM™ IMAGE VISUALIZATION DEVICE
Encore Creativity for Older Adults Receives $1M Donation for Brain Health Initiatives
02 nov. 2023 09h52 HE
|
Encore Creativity for Older Adults
Encore Creativity for Older Adults receives gift pledge of $1M to expand music programs for those with cognitive change
AAPA, PA Foundation, Cleveland Clinic, and Davos Alzheimer’s Collaborative Release Early Cognitive Assessment Toolkit
01 nov. 2023 09h26 HE
|
American Academy of PAs
ALEXANDRIA, VA, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The American Academy of Physician Associates (AAPA), PA Foundation (PAF), Cleveland Clinic, and Davos Alzheimer’s Collaborative (DAC) today publicly...
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
31 oct. 2023 09h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two...
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
26 oct. 2023 09h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, today reports novel findings for its lead product, pepinemab, in a...
Alzheimer’s Leaders Discuss How to Shift Science into Clinical Practice During National Alzheimer’s Summit
20 oct. 2023 12h58 HE
|
UsAgainstAlzheimer's
Washington, DC, Oct. 20, 2023 (GLOBE NEWSWIRE) -- UsAgainstAlzheimer’s this week hosted the 2023 National Alzheimer’s Summit, a groundbreaking event dedicated to applying recent scientific and...
Breakthrough Study: Alzheimer’s Patients Benefit from Lifestyle Coaching (Not Drugs)
16 oct. 2023 08h00 HE
|
Posit Science
Study shows lifestyle change by pre-dementia and Alzheimer's patients drove better cognitive performance than generally seen in trials of Alzheimer's drugs
Vaccinex, Inc. Announces Reverse Stock Split
22 sept. 2023 16h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...